Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|April 1, 2017

BioPharm International

  • BioPharm International-04-01-2017
  • Volume 30
  • Issue 4

Nanoparticle Deagglomeration Technology

The Thinky PR-1 Nanoparticle Dispersion Machine from Intertronics is a desktop unit that can disperse carbon nanotubes (CNT), graphene, and other 2D nanomaterials within a closed container.

The Thinky PR-1 Nanoparticle Dispersion Machine from Intertronics is a desktop unit that can disperse carbon nanotubes (CNT), graphene, and other 2D nanomaterials within a closed container. The dispersion is consistent, highly reproducible, and is typically accomplished in a few minutes. The Thinky PR-1 uses mechanical rotation and multi-directional ultrasonics to achieve a rapid and even particle dispersion. The machine has a temperature limit control in the ultrasonic bath to counter the temperature rise of water and materials as a result of ultrasonic energy, avoiding changes in physical material properties. The system is compatible with quantities as small as a 5 mL capacity vial to a 200 mL capacity stainless steel container. The Thinky PR-1 can be used for applications in drug delivery, imaging, tissue engineering, and biosensors. 

Intertronics 
 


Related to this article

The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.